Related Experiment Video
Updated: Mar 30, 2026

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
Bringing regenerative medicines to the clinic: the future for regulation and reimbursement
Tania Bubela1, Christopher McCabe2, Peter Archibald3
1School of Public Health, 3-279 Edmonton Clinic Health Academy, 11405-87 Avenue, University of Alberta, Edmonton, AB, T6G 1C9, Canada.
Abstract:
Significant investments in regenerative medicine necessitate discussion to align evidentiary requirements and decision-making considerations from regulatory, health system payer and developer perspectives. Only with coordinated efforts will the potential of regenerative medicine be realized. We report on discussions from two workshops sponsored by NICE, University of Alberta, Cell Therapy Catapult and Centre for Commercialization of Regenerative Medicine. We discuss methods to support the assessment of value for regenerative medicine products and services and the synergies that exist between market authorization and reimbursement regulations and practices. We discuss the convergence in novel adaptive licensing practices that may promote the development and adoption of novel therapeutics that meet the needs of healthcare payers.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Drug Products: Biologics, Biosimilars and Interchangeables
Regulation of Hematopoietic Stem Cells
Drug Regulation
Mesenchymal Stem Cells
Overview of Regeneration and Repair
Regeneration
All animals have varying degrees of...

